WAVE Life Sciences (STU:1U5) Cash per Share : €1.89 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). WAVE Life Sciences's Cash per Share for the quarter that ended in Dec. 2024 was €1.89.

WAVE Life Sciences Cash per Share Historical Data

The historical data trend for WAVE Life Sciences's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Cash per Share Chart

WAVE Life Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash per Share

Get a 7-Day Free Trial

3.11

2.23

0.96

1.54

1.89

WAVE Life Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash per Share	Get a 7-Day Free Trial															1.54	1.36	1.17	1.89	1.89

WAVE Life Sciences Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

WAVE Life Sciences's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	288.484	/	153.0
	=	1.89

WAVE Life Sciences's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	288.484	/	153.0
	=	1.89

WAVE Life Sciences (STU:1U5) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

WAVE Life Sciences Cash per Share Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

WAVE Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

WVE:USA 1U5:Germany

Address

7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936

Website

https://www.wavelifesciences.com

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

WAVE Life Sciences Headlines

No Headlines